Navigation Links
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
Date:4/25/2009

- Combination of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency in reducing viral load in patients with hepatitis C -

NUTLEY, N.J., BRISBANE, Calif., and PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Roche, InterMune, Inc. (Nasdaq: ITMN) and Pharmasset (Nasdaq: VRUS) today announced the first results from their innovative, interferon-free regimen of direct acting antiviral (DAA) combination therapy for the treatment of patients chronically infected with the hepatitis C virus (HCV)(1). The study combined two oral DAAs, R7227 (also known as ITMN-191) and R7128, for the first time in patients. There were no serious adverse events reported during the 14 days of dosing, and the reductions in levels of HCV RNA were significant.

Results of the INFORM-1 study were presented today during the late-breaker session at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen.

The trial, conducted in centers in New Zealand and Australia, is the first to investigate the combination of two oral antiviral medicines in the absence of interferon and ribavirin. The results demonstrated for the first time that the combination of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV viral load reduction in patients with HCV. Roche is developing R7227, a protease inhibitor, with InterMune, and R7128, a nucleoside polymerase inhibitor, with Pharmasset.

Further studies will test the activity and safety of the combination of R7227 and R7128 with and without interferon and/or ribavirin. The current standard of care for HCV is a combination of pegylated interferon plus ribavirin, w
'/>"/>

SOURCE Roche; InterMune; Pharmasset
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
7. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
8. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
9. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
10. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
11. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... and IRVINE, Calif., May 6, 2011 CryoLife, Inc. ... device and cardiovascular tissue processing company, today announced the ... through its wholly owned subsidiary CL Falcon, Inc., for ... ("Cardiogenesis") (OTCQB: CGCP).  The tender offer expired at 12:00 ...
... The Female Health Company (NASDAQ-CM: FHCO) today announced ... Comercio (Semina), was successful in a public tender to ... to 20 million FC2 Female Condoms.  The contract is ... will be determined at the Ministry of Health,s discretion. ...
Cached Medicine Technology:CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 2CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 3CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 4CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 5CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 6The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3
(Date:8/30/2014)... 2014 Hands On Mobile ... offers the complete spa experience combining elegant decor, ... the most important ingredient of all, states Marla ... pro's! People will enjoy the get-away feel, without ... website reads, "Step into the spacious, luxurious spa ...
(Date:8/30/2014)... 2014 Daily Gossip magazine reveals in ... and panic attacks under control with a simple and ... describes this new method as an anxiety recovery ... and overcome general anxiety related disorders. , What ... fact that it can be accessed by users from ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... Nutrition and Pharameuticals. Nutraceuticals is a source of ... ingredients from natural food sources. Nutraceutical ingredients have ... to the human body. Nutraceutical health products include ... fortified foods and more. Although nature is the ...
(Date:8/30/2014)... Hicksville, NY (PRWEB) August 30, 2014 ... Organizations throughout the planet has been one of ... in order to create a positive impact around ... aesthetics and staffed with top trained executives and ... millions of people worldwide. Vital statistics demonstrate ...
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 ... Disruptor Industry, 2009-2019 is a professional and in-depth ... industry. The report firstly reviews the basic information ... manufacturing technology. The report then explores global and ... product specification, capacity, Production value, and market share ...
Breaking Medicine News(10 mins):Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4
... The earliest known case of coronary artery disease has been ... lived between 1580 and 1550 B.C., and died in her ... scans found that this wasn,t a unique case. About 45 ... an accumulation of plaque in arteries. The findings ...
... a genetic characteristic of metastatic prostate cancer that defines ... published in Cancer Discovery , the newest journal ... debut at the AACR 102nd Annual Meeting 2011, held ... an investigator of the Howard Hughes Medical Institute and ...
... laboratory and epidemiologic data to find that men using the ... prostate cancer. The scientists say further research about the ... ones that work the same way, to treat the cancer. ... for centuries in folk medicine and for decades to treat ...
... bladder cancer risk and to the length of protective caps ... of Texas MD Anderson Cancer Center reported today at the ... telomeres, guard against chromosomal damage and genomic instability that can ... single point of variation in the genome strongly associated with ...
... use has been linked to thicker arteries, possibly contributing to ... of twin veterans. The data is being presented Tuesday, April ... Orleans. Depression can heighten the risk for heart disease, ... is separate and independent from depression itself, says first author ...
... hedgehog pathway inhibitor demonstrated efficacy in preventing and treating ... syndrome, a rare inheritable disease, according to Phase II ... held April 2-6. In 1996, Ervin Epstein Jr., ... Institute, and colleagues identified the site of the mutation ...
Cached Medicine News:Health News:Mummies Show Heart Disease Is an Ancient Problem 2Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 2Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 3Health News:Genetic variation cuts bladder cancer risk, protects chromosome tips 2Health News:Genetic variation cuts bladder cancer risk, protects chromosome tips 3Health News:Antidepressants linked to thicker arteries 2Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 2Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 3
Used for stone manipulation and removal in the urinary tract. The hollow shaft allows protected delivery of a laser fiber to an entrapped stone for fragmentation of the stone. Supplied sterile in pee...
... Tipless Design, ZeroTip basket features ... negotiation and close stone approximation., Flexible ... deflection for efficient retrieval of calyceal ... passed through a 3.6Fr working channel, ...
... Tip 12 Inch , 20 inch,PVC, Length ... Available in 3,4,5 6Fr. These top quality ... flexible polymer material and have standard screw ... They are manufactured to the highest standards. ...
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)...
Medicine Products: